Lithium Carbonate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Lithium Carbonate: From Its Current US-Marketed Use to Pseudoachondroplasia
One-Sentence Summary
Lithium carbonate is an established oral drug that is widely marketed in the United States. The TxGNN model predicts it may be effective for pseudoachondroplasia, a rare skeletal dysplasia. This prediction has 0 clinical trials and 0 publications behind it, so it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Pseudoachondroplasia |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. The approved indication text was also not provided in the source data. The link between lithium carbonate and this disease therefore cannot be verified from the input.
One speculative mechanism is worth noting. Lithium is known to inhibit GSK-3 and modulate Wnt signaling, and these pathways are involved in chondrocyte biology. That could make it relevant to skeletal dysplasias. This is a hypothesis only, and no supporting data was provided.
The high score (99.98%) may partly reflect knowledge-graph proximity among skeletal dysplasia nodes rather than a validated pharmacological relationship. It should be treated as a lead for investigation, not as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The source data lists no approved indication text for these products.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA204779 | Lithium Carbonate | Tablet, extended release | RemedyRepack Inc. |
| ANDA076832 | Lithium Carbonate | Tablet, extended release | Hikma Pharmaceuticals USA Inc. |
| ANDA076691 | Lithium Carbonate | Tablet, extended release | Hikma Pharmaceuticals USA Inc. |
| ANDA079139 | Lithium Carbonate | Capsule | NCS HealthCare of KY, LLC dba Vangard Labs |
| ANDA079139 | Lithium Carbonate | Capsule | American Health Packaging |
The other marketed forms are oral tablets, gelatin-coated capsules and pellets.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score. There are no trials or publications, and the mechanism of action is unavailable. Among the other nine predicted indications, only brachyolmia-amelogenesis imperfecta syndrome has any literature: a general 2019 review of genetic skeletal disorders (PMID 31888683). Its content on lithium is unconfirmed.
To proceed, the following is needed:
- Mechanism of action data (e.g., from DrugBank)
- Package insert warnings and contraindications for a safety screen
- A targeted literature search on lithium, GSK-3/Wnt signaling and chondrocyte or skeletal dysplasia models
- Preclinical evidence, such as cell or animal model data, before any clinical consideration
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.